Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,912 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT06229041RecruitingPhase 3
Chemo and radiation with or without immunotherapy for high-risk rectal cancer
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
BeijingAges 18–75 - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18 - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT06273800Recruiting
Chemo timing and the menstrual cycle in breast cancer
This study tests whether the timing of chemotherapy during your menstrual cycle affects how well it works in triple-negative breast cancer. Women with regular periods who are about to start chemo before surgery may be eligible.
Amsterdam, North HollandAges 18–59 - NCT06331455RecruitingPhase 2
Radiation, immunotherapy, and surgery for chest wall lung cancer
This trial tests combining radiation, immunotherapy (durvalumab), and surgery for people with non-small cell lung cancer that has spread to the chest wall or top of the lung. It aims to see if this approach can help remove the cancer completely.
TorontoAges 18–99 - NCT06353906RecruitingPhase 2
Chemo plus immunotherapy for advanced penile cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
LeuvenAges 18 years+ - NCT06383559RecruitingPhase 2
Combination therapy for advanced AFP-positive gastric cancer
This trial tests a new combination of chemotherapy (XELOX) plus two immunotherapy/targeted drugs (Sintilimab and Lenvatinib) in people with advanced stomach cancer that produces a high level of a protein called AFP. It aims to see if this combination is safe and can shrink tumors when given as the first treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06398314Recruiting
Palliative radiation for pelvic tumor symptoms
This trial tests a type of radiation to help relieve symptoms like pain, bleeding, or other discomfort from tumors in the pelvic area. It is for people whose cancer has spread or cannot be cured, and who are not able to have stronger treatments.
ÅlesundAges 18 years+ - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT06452394RecruitingPhase 2
Testing doxycycline with chemo for breast cancer
This trial tests whether adding the antibiotic doxycycline to standard chemotherapy before surgery can better target breast cancer stem cells in people with ER-positive, HER2-negative breast cancer. The goal is to improve treatment response.
Sankt Gallen, Canton of St. GallenAges 18 years+ - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT06481566Recruiting
Almonertinib plus radiation for EGFR-mutant lung cancer
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06487221RecruitingPhase 2
Avutometinib and Defactinib for diffuse stomach cancer
This trial tests two oral drugs, avutometinib and defactinib, for people with a specific type of stomach cancer called diffuse gastric cancer. The goal is to see if these drugs can help shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT06495125RecruitingPhase 2
Study of three drugs for a type of advanced lung cancer
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Atlanta, GeorgiaAges 18 years+ - NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06538038Recruiting
Osimertinib plus chemo vs. osimertinib alone for EGFR-mutated NSCLC
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
Birmingham, AlabamaAges 18 years+ - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT06543537Recruiting
A trial to help patients with advanced ovarian cancer plan their visits
This study tests a program to help patients and their doctors work together to set a plan for each visit. If you have advanced ovarian cancer and are getting chemotherapy at Dana-Farber, you may be able to join.
Boston, MassachusettsAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,912 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.